- Home
- / Celldex Therapeutics
Celldex Therapeutics
Stock Price
$26.9
2024-10-29
Market Capitalization
$1.9 B
2024-10-29
Revenue
$1.5 M
FY, 2025
Celldex Therapeutics Summary
Company Summary
- Overview
- Celldex Therapeutics (formerly Avant Immunotherapeutics) is a biopharmaceutical company that specializes in monoclonal and bispecific antibody development. It offers a bispecific antibody platform to support pipeline expansion with additional candidates for inflammatory diseases and oncology.
- Type
- Public
- Status
- Active
- Founded
- 1983
- HQ
- Hampton, NJ, US | view all locations
- Website
- https://celldex.com/
- Cybersecurity rating
- ESG rating
Table of Contents
Key People
Sarah Boylan Cavanaugh, Senior Vice President, Corporate Affairs & Administration
Tibor Keler, Founder, Executive Vice President & Chief Scientific Officer
Thomas Davis, CMO, SVP Clinical Development
Operating MetricsView all
Patents Issued
300
FY, 2016
LocationsView all
4 locations detected
Hampton, NJ HQ
United States
53 Frontage Rd #220
Fall River, MA
United States
151 martine street
Needham, MA
United States
160 Gould St #202
New Haven, CT
United States
300 George St #530
Celldex Therapeutics Financials
Summary Financials
- Revenue (Q1, 2026)
- $15.0K
- Net income (Q1, 2026)
- ($78.7M)
- Cash (Q1, 2026)
- $35.7M
- EBIT (Q1, 2026)
- ($84.4M)
- Enterprise value
- $1.8B